Evidence map›Paper›PMID 40256131›Full record

ArticleHealth science reports2025

The Gut-Brain Axis in Irritable Bowel Syndrome: Implementing the Role of Microbiota and Neuroimmune Interaction in Personalized Prevention-A Narrative Review.

Fatima Soufan, Abir Ghosson, Rayyan Jaber, Adel Ghandour, Olivier Uwishema

Abstract read
In one paragraph

Article in Health science reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Fatima SoufanDepartment of Research and Education Oli Health Magazine Organization Kigali Rwanda.ORCID 0009-0002-4220-213X
Abir GhossonDepartment of Research and Education Oli Health Magazine Organization Kigali Rwanda.ORCID 0009-0004-7698-5632
Rayyan JaberDepartment of Research and Education Oli Health Magazine Organization Kigali Rwanda.ORCID 0009-0004-5876-8810
Adel GhandourDepartment of Research and Education Oli Health Magazine Organization Kigali Rwanda.ORCID 0009-0005-5126-6743
Olivier UwishemaDepartment of Research and Education Oli Health Magazine Organization Kigali Rwanda.ORCID 0000-0002-0692-9027

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Purpose: Irritable bowel syndrome (IBS) is a disorder characterized by microbiota-neuroimmune interaction resulting in disturbance to the gut-brain axis (GBA). The purpose of this review is to garner an overview of the different pathophysiological mechanisms indicated in the development of IBS and the associated sequalae on gut microbiota alongside its role in the GBA. Moreover, we aim to provide an insight into the possibility of utilizing personalized medicine when managing said affected populations. Methods: A comprehensive review was performed of the relevant literature pertaining to the current state of GBA alteration implicated in IBS, comprising microbiota-neuroimmune interaction alongside disturbance and activation, respectively. Different search databases were utilized, including PubMed/MEDLINE and ScienceDirect. Results: The review demonstrated the most evident etiologies of IBS being the imbalance of microbiota and the alteration to the GBA. Furthermore, the interrelation between microbiota and neuroimmunity was discussed. Promising avenues for IBS prevention and management are offered through emerging research on the pathophysiological mechanisms indicated in IBS-associated GBA alteration. This entails a role for the involved interactions between microbiota modification and neuroimmunity activation. Conclusion: Promising prospects for symptom prevention and management are signaled by the possibility of personalized therapy specifically designed to address the GBA dysfunction indicated in IBS. Policymakers and developers should encourage further study and allocate available resources to aid researchers in the implementation and identification of novel preventive therapeutics. Furthermore, physicians should advocate and integrate the use of personalized medical approaches of IBS to help ensure a better quality of life.

Indexed as

dysbiosisirritable bowel syndromemicrobiotamicrobiota–gut–brain axispersonalized medicine

Identifiers

PMID40256131
PMCPMC12006843

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.